Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2006, 150(2):255-259 | DOI: 10.5507/bp.2006.037

PROGNOSTIC VALUE OF hMLH1 AND hMSH2 IMMUNOHISTOCHEMICAL EXPRESSION IN NON-SMALL CELL LUNG CANCER. A TISSUE MICROARRAY STUDY

Jozef Skardaa, Eduard Fridmanb, Pavlina Plevovaa, Marian Hajduchc, Lenka Radovac, Efrat Ofekb, Jury Kopolovicb, Vitezslav Kolekd, Zdenek Kolara
a Department of Pathology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
b Laboratory of Experimental Medicine, Departments of Pediatrics and Oncology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
c Department of Pathology, The Chaim Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel
d Department of Tuberculosis and Respiratory Diseases Faculty of Medicine and Dentistry, Palacky University, Olomouc

Background: hMLH1 and hMSH2 genes are both known to play a role in DNA mismatch repair. Nonetheless, the clinical significance of hMLH1 and hMSH2 protein expression in lung cancers remains unclear.

Aim: The aim of this study was to investigate the immunohistochemical expression of hMLH1 and hMSH2 proteins in tumor specimens from 179 non-small cell lung cancer (NSCLC) patients using a tissue microarray technique and to correlate these results with other clinicopathological variables, including the disease specific and overall survivals.

Method: hMLH1 and hMSH2 protein expression was evaluated by immunohistochemistry using monoclonal antibodies G168-728 for hMLH1 and FE11 for hMSH2 protein expression analysis. The Pearson χ2 test was used to compare the hMLH1 and hMSH2 alterations among the cases and between various clinical and laboratory variables. P < or = 0.05 was considered statistically significant.

Results: Alteration of hMLH1 and hMSH2 protein expression was observed in 10 % of patients. No significant correlation was found between the protein expression and patient age, smoking status, tumor histology or disease stage and disease free and overall survival.

Conclusions: Alterations in the expression of hMLH1 and hMSH2 proteins did not have any prognostic value in stage III. NSCLC patients.

Keywords: Non-small cell lung cancer, Prognosis, Mismatch repair, hMLH1, hMSH2, Tissue microarray

Received: May 5, 2006; Accepted: June 16, 2006; Published: December 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Skarda, J., Fridman, E., Plevova, P., Hajduch, M., Radova, L., Ofek, E., ... Kolar, Z. (2006). PROGNOSTIC VALUE OF hMLH1 AND hMSH2 IMMUNOHISTOCHEMICAL EXPRESSION IN NON-SMALL CELL LUNG CANCER. A TISSUE MICROARRAY STUDY. Biomedical papers, 150(2), 255-259. doi: 10.5507/bp.2006.037
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Aubry MC, Halling KC, Myers JL, Tazelaar HD, Yang P, Thibodeau SN. DNA mismatch repair genes hMLH1, hMSH2, and hMSH6 are not inactivated in bronchioloalveolar carcinomas of the lung. Cancer 2001; 92:2898-901. Go to original source... Go to PubMed...
    2. Brooks KR, To K, Joshi MB, Conlon DH, Herndon JE, DAmico TA, Harpole DH Jr. (2003) Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: a novel approach for patient selection. Ann Thorac Surg 76:187-93. Go to original source... Go to PubMed...
    3. Chang JW, Chen YC, Chen CY, Chen JT, Chen SK, Wang YC. Correlation of genetic instability with mismatch repair protein expression and p53 mutations in non-small cell lung cancer. Clin Cancer Res 2000; 6:1639-46.
    4. Chiu YL, Yu TS, Wong TW. Time trends of female lung cancer in Hong Kong: age, period and birth cohort analysis. Int J Cancer 2004; 111:424-30. Go to original source... Go to PubMed...
    5. Deguchi M, Shiina H, Igawa M, Kaneuchi M, Nakajima K, Dahiya R. DNA mismatch repair genes in renal cell carcinoma. J Urol 2003; 169:2365-71. Go to original source... Go to PubMed...
    6. de Perrot M, Licker M, Bouchardy C, Usel M, Robert J, Spiliopoulos A. Sex differences in presentation, management, and prognosis of patients with non-small cell lung carcinoma. J Thorac Cardiovasc Surg 2000; 119:21-6. Go to original source... Go to PubMed...
    7. Deng G, Peng E, Gum J, Terdiman J, Sleisenger M, Kim YS (2002) Methylation of hMLH1 promoter correlates with the gene silencing with a region-specific manner in colorectal cancer. Br J Cancer 86:574-9. Go to original source... Go to PubMed...
    8. Dodds L, Davis S, Polisson L. A population-based study of lung cancer incidence trends by histological type. J Natl Cancer Inst 1974; 76:21-9.
    9. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001; 61:3225-9. Go to original source...
    10. Esteller M, Levine R, Baylin SB, Ellenson LH, Herman JG. MLH1 promoter hypermethylation is associated with microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene 1998; 16:2413-7. Go to original source... Go to PubMed...
    11. Hansen LT, Thykjaer T, Orntoft TF, Rasmussen LJ, Keller P, Spang- Thomsen M, Edmonston TB, Schmutte C, Fishel R, Petersen LN. The role of mismatch repair in small-cell lung cancer cells. Eur J Cancer 2003; 39:1456-67. Go to original source... Go to PubMed...
    12. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, Markowitz S, Willson JK, Hamilton SR, Kinzler KW, Kane MF, Kolodner RD, Vogelstein B, Kunkel TA, Baylin SB. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A 1998; 95:6870- 5. Go to original source... Go to PubMed...
    13. Ko YC, Wang JL, Wu CC, Huang WT, Lin MC. Lung cancer at a medical center in Southern Taiwan. Chang Gung Med J. 2005; 28(6):387-95 Go to original source... Go to PubMed...
    14. Lam WK, So SY, Yu DYC. Clinical features of bronchogenic carcinoma in Hong Kong: review of 480 patients. Cancer 1983; 52:369-76. Go to original source... Go to PubMed...
    15. Leung SY, Yuen ST, Chung LP, Chu KM, Chan ASY, Ho JCI. hMLH1 promoter methylation and lack of hMLH1 expression in sporadic gastric carcinomas with high-frequency microsatellite instability. Cancer Res 1999; 59:159-64. Go to PubMed...
    16. Lienert T, Serke M, Schonfeld N, Loddenkemper R. Lung cancer in young females. Eur Respir J 2000; 16:986-90. Go to original source... Go to PubMed...
    17. Mackay HJ, Cameron D, Rahilly M, Mackean MJ, Paul J, Kaye SB, Brown R. Reduced MLH1 expression in breast tumors after primary chemotherapy predicts disease-free survival. J Clin Oncol 2000; 18:87-93. Go to original source... Go to PubMed...
    18. Minami H, Yoshimura M, Miyamoto Y, Matsuoka H, Tsubota N. Lung cancer in Women. Sex-associated differences in survival of patients undergoing resection for lung cancer. Chest 2000; 118:1603-9. Go to original source... Go to PubMed...
    19. Ryberg D, Hewer A, Phillips DH, Haugen A. Different susceptibility to smoking-induced DNA damage among male and female lung cancer patients. Cancer Res 1994; 54:5801-3.
    20. Rhyu MS. Molecular mechanisms underlying hereditary nonpolyposis colorectal carcinoma J Natl Cancer Inst 1996; 88:240-51. Go to original source... Go to PubMed...
    21. Stolley PD. Lung cancer in women: five years later, situation worse. N Engl J Med 1983; 309:428-9. Go to original source... Go to PubMed...
    22. Strathdee G, MacKean MJ, Illand M, Brown R. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 1999; 18:2335-41. Go to original source... Go to PubMed...
    23. Takagi Y, Koo LC, Osada H, Ueda R, Kyaw K, Ma CC, Suyama M, Saji S, Takahashi T, Tominaga S, et al. Distinct mutational spectrum of the p53 gene in lung cancers from Chinese women in Hong Kong. Cancer Res 1995; 55:5354-7.
    24. Xinarianos G, Liloglou T, Prime W, Maloney P, Callaghan J, Fielding P, Gosney JR, Field JK. hMLH1 and hMSH2 expression correlates with allelic imbalance on chromosome 3p in non-small cell lung carcinomas. Cancer Res 2000; 60:4216-21. Go to PubMed...
    25. Wang YC, Lu YP, Tseng RC, Lin RK, Chang JW, Chen JT, Shih CM, Chen CY. Inactivation of hMLH1 and hMSH2 by promoter methylation in primary non-small cell lung tumors and matched sputum samples. J Clin Invest 2003; 111:887-95. Go to original source... Go to PubMed...

    Return to the content